MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
0.4482
+0.0527
+13.32%
After Hours: 0.4542 +0.006 +1.34% 19:39 11/06 EST
OPEN
0.4100
PREV CLOSE
0.3955
HIGH
0.4493
LOW
0.3999
VOLUME
5.16M
TURNOVER
--
52 WEEK HIGH
1.680
52 WEEK LOW
0.3370
MARKET CAP
124.51M
P/E (TTM)
-0.9156
1D
5D
1M
3M
1Y
5Y
1D
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note
NASDAQ · 1d ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 2d ago
Humacyte Announces Three Presentations At American Heart Association Scientific Sessions, November 6–9; Two Additional Presentations To Cover First-In-Human Phase 2a Study Design And Preclinical Results For Its Investigational Coronary Tissue Engineered Vessel
Benzinga · 4d ago
Weekly Report: what happened at HUMA last week (1026-1030)?
Weekly Report · 5d ago
Humacyte issued new U.S. patent covering Symvess
TipRanks · 10/28 12:21
Weekly Report: what happened at HUMA last week (1019-1023)?
Weekly Report · 10/26 10:07
Humacyte's ATEV Shows Phase 3 Benefits In Women, Supports Planned FDA Label Expansion
NASDAQ · 10/23 17:15
Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026
Benzinga · 10/23 12:03
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.